CombiMatrix rises on deal with pathology service provider

|About: CombiMatrix Corporation (CBMX)|By:, SA News Editor

Pathology service provider ProPath selects CombiMatrix (CBMX) to "provide its chromosomal microarray analysis testing for miscarriage analysis."

"For an important group of patients, CMA testing can play a significant role in a comprehensive miscarriage analysis," a ProPath director notes.

CBMX says the agreement is "yet another validation of the quality of [its] diagnostic services." (PR)

CBMX +14% premarket.